Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
2.

Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis.

Gutierrez MJ, Desiderio SV, Wang NY, Darrah E, Cappelli L, Nino G, Jones M, Bingham CO 3rd.

J Immunol Res. 2019 Apr 28;2019:3658215. doi: 10.1155/2019/3658215. eCollection 2019.

3.

Dissemination strategies for core outcome set recommendations: A survey of Delphi panelists and activity profile of a research infrastructure project.

Akinremi A, Turnbull AE, Chessare CM, Bingham CO 3rd, Needham DM, Dinglas VD.

J Clin Epidemiol. 2019 Jun 4. pii: S0895-4356(19)30106-4. doi: 10.1016/j.jclinepi.2019.05.026. [Epub ahead of print]

PMID:
31173895
4.

Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Jun 4;20(1):322. doi: 10.1186/s13063-019-3463-8.

5.

Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis.

Heisler AC, Song J, Dunlop DD, Wohlfahrt A, Bingham CO 3rd, Bolster MB, Clauw DJ, Marder W, Phillips K, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Jun 4. doi: 10.1002/acr.23994. [Epub ahead of print]

PMID:
31162824
6.

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.

Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE.

Arthritis Res Ther. 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1.

7.

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Erratum in: Trials. 2019 Jun 4;20(1):322.

8.

Sonographic findings from inflammatory arthritis due to antisynthetase syndrome.

Miller JB, Danoff SK, Bingham CO 3rd, Paik JJ, Mecoli CA, Tiniakou E, Christopher-Stine L, Albayda J.

Clin Rheumatol. 2019 May;38(5):1477-1483. doi: 10.1007/s10067-019-04471-y. Epub 2019 Feb 27.

PMID:
30810913
9.

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Andersen KM, Kelly A, Lyddiatt A, Bingham CO 3rd, Bykerk VP, Batterman A, Westreich J, Jones MK, Cross M, Brooks PM, March L, Shea B, Tugwell P, Simon LS, Christensen R, Bartlett SJ.

J Rheumatol. 2019 Feb 15. pii: jrheum.181185. doi: 10.3899/jrheum.181185. [Epub ahead of print]

PMID:
30770516
10.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181096. doi: 10.3899/jrheum.181096. [Epub ahead of print]

PMID:
30770515
11.

Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018.

Craig ET, Orbai AM, Mackie S, Bartlett SJ, Bingham CO 3rd, Goodman S, Hill C, Holt R, Leong A, Karyekar C, Leung YY, Richards P, Halls S.

J Rheumatol. 2019 Feb 15. pii: jrheum.181074. doi: 10.3899/jrheum.181074. [Epub ahead of print]

PMID:
30770511
12.

OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies.

Regardt M, Mecoli CA, Park JK, de Groot I, Sarver C, Needham M, de Visser M, Shea B, Bingham CO III, Lundberg IE, Song YW, Christopher-Stine L, Alexanderson H.

J Rheumatol. 2019 Feb 15. pii: jrheum.181065. doi: 10.3899/jrheum.181065. [Epub ahead of print]

PMID:
30770504
13.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181097. doi: 10.3899/jrheum.181097. [Epub ahead of print]

PMID:
30770502
14.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.

Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, Clairman H, Bingham CO 3rd, Thornhill S, Strand V, Alongi A, Magni-Manzoni S, van Rossum MAJ, Vesely R, Vojinovic J, Brunner HI, Harris JG, Horton DB, Lovell DJ, Mannion M, Rahimi H, Ravelli A, Ringold S, Ruperto N, Schrandt MS, Shenoi S, Shiff NJ, Toupin-April K, Tzaribachev N, Weiss P, Consolaro A.

J Rheumatol. 2019 Feb 15. pii: jrheum.181088. doi: 10.3899/jrheum.181088. [Epub ahead of print]

PMID:
30770499
15.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 1. pii: jrheum.181218. doi: 10.3899/jrheum.181218. [Epub ahead of print]

PMID:
30709952
16.

Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O.

Ann Rheum Dis. 2019 Jun;78(6):860-862. doi: 10.1136/annrheumdis-2018-214748. Epub 2019 Jan 18. No abstract available.

PMID:
30659050
17.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck A, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Jan 15. pii: jrheum.181123. doi: 10.3899/jrheum.181123. [Epub ahead of print]

PMID:
30647191
18.

Successful Methotrexate Treatment of Chronic Chikungunya Arthritis.

Amaral JK, Bingham CO 3rd, Schoen RT.

J Clin Rheumatol. 2018 Dec 5. doi: 10.1097/RHU.0000000000000943. [Epub ahead of print] No abstract available.

PMID:
30520824
19.

Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis.

Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO 3rd, Shah AA.

Rheumatology (Oxford). 2018 Nov 30. doi: 10.1093/rheumatology/key358. [Epub ahead of print]

PMID:
30508191
20.

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Darrah E, Giles JT, Davis RL, Naik P, Wang H, Konig MF, Cappelli LC, Bingham CO 3rd, Danoff SK, Andrade F.

Front Immunol. 2018 Nov 20;9:2696. doi: 10.3389/fimmu.2018.02696. eCollection 2018.

21.

Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis.

DiRenzo D, Crespo-Bosque M, Gould N, Finan P, Nanavati J, Bingham CO 3rd.

Curr Rheumatol Rep. 2018 Oct 18;20(12):75. doi: 10.1007/s11926-018-0787-4. Review.

22.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

23.

Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.

Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L.

J Rheumatol. 2019 Jan;46(1):106-111. doi: 10.3899/jrheum.180353. Epub 2018 Sep 15.

PMID:
30219767
24.

Pain and Catastrophizing in Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study.

Cohen EM, Edwards RR, Bingham CO 3rd, Phillips K, Bolster MB, Moreland LW, Neogi T, Marder W, Wohlfahrt A, Clauw D, Lee YC.

J Clin Rheumatol. 2018 Jun 22. doi: 10.1097/RHU.0000000000000834. [Epub ahead of print]

PMID:
30035754
25.

A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation.

Turnbull AE, Dinglas VD, Friedman LA, Chessare CM, Sepúlveda KA, Bingham CO 3rd, Needham DM.

J Clin Epidemiol. 2018 Oct;102:99-106. doi: 10.1016/j.jclinepi.2018.06.007. Epub 2018 Jun 30.

PMID:
29966731
26.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2018 Jul;45(7):1071. doi: 10.3899/jrheum.161252.C2. No abstract available.

PMID:
29961681
27.

Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Wohlfahrt A, Bingham CO 3rd, Marder W, Phillips K, Bolster MB, Moreland LW, Zhang Z, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):521-529. doi: 10.1002/acr.23617.

PMID:
29885039
28.

Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.

Bartlett SJ, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Ginsberg S, Leong AL, Lyddiatt A, Nowell WB, Orbai AM, Smith KC, Bingham CO 3rd.

Qual Life Res. 2018 Sep;27(9):2443-2451. doi: 10.1007/s11136-018-1880-x. Epub 2018 May 24.

PMID:
29797175
29.

Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency.

Gutierrez MJ, Sullivan KE, Fuleihan R; USIDNET Consortium, Bingham CO 3rd.

Semin Arthritis Rheum. 2018 Oct;48(2):318-326. doi: 10.1016/j.semarthrit.2018.02.013. Epub 2018 Feb 23.

PMID:
29599028
30.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

PMID:
29573850
31.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

32.

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Albayda J, Bingham CO 3rd, Shah AA, Kelly RJ, Cappelli L.

Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. doi: 10.1093/rheumatology/kex470. No abstract available.

33.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO 3rd, Ritchlin CT, Schwarz EM.

Nat Rev Rheumatol. 2018 Feb;14(2):94-106. doi: 10.1038/nrrheum.2017.205. Epub 2018 Jan 11. Review.

34.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2017 Dec;44(12):1944. doi: 10.3899/jrheum.161252.C1. No abstract available.

PMID:
29196552
35.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

36.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

37.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

38.

Towards improving measurement of stiffness in rheumatology.

Orbai AM, Bingham CO 3rd.

Rheumatology (Oxford). 2018 Feb 1;57(2):206-208. doi: 10.1093/rheumatology/kex247. No abstract available.

PMID:
28968882
39.

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO 3rd.

J Rheumatol. 2017 Dec;44(12):1884-1888. doi: 10.3899/jrheum.161389. Epub 2017 Aug 15.

40.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

PMID:
28811351
41.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

42.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2017 Nov;44(11):1683-1687. doi: 10.3899/jrheum.161252. Epub 2017 Aug 1. Erratum in: J Rheumatol. 2017 Dec;44(12 ):1944. J Rheumatol. 2018 Jul;45(7):1071.

43.

Perspectives of survivors, families and researchers on key outcomes for research in acute respiratory failure.

Dinglas VD, Chessare CM, Davis WE, Parker A, Friedman LA, Colantuoni E, Bingham CO, Turnbull AE, Needham DM.

Thorax. 2018 Jan;73(1):7-12. doi: 10.1136/thoraxjnl-2017-210234. Epub 2017 Jul 29.

PMID:
28756400
44.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.

Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

45.

Erosive Rheumatoid Arthritis After Bilateral Hand Transplantation.

Adler BL, Albayda J, Shores JT, Lee WPA, Brandacher G, Bingham CO 3rd.

Ann Intern Med. 2017 Aug 1;167(3):216-218. doi: 10.7326/L16-0588. Epub 2017 Jun 27. No abstract available.

PMID:
28654973
46.

Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition.

Dein E, Sharfman W, Kim J, Gellad F, Shah AA, Bingham CO 3rd, Cappelli LC.

J Immunother. 2017 Oct;40(8):312-314. doi: 10.1097/CJI.0000000000000174.

47.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

48.

Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study.

Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, Turnbull AE.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130. doi: 10.1164/rccm.201702-0372OC.

49.

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis.

Cappelli LC, Palmer JL, Kremer J, Bingham CO 3rd.

Semin Arthritis Rheum. 2017 Oct;47(2):165-169. doi: 10.1016/j.semarthrit.2017.03.024. Epub 2017 Apr 1.

50.

Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.

Lee YC, Bingham CO 3rd, Edwards RR, Marder W, Phillips K, Bolster MB, Clauw DJ, Moreland LW, Lu B, Wohlfahrt A, Zhang Z, Neogi T.

Arthritis Care Res (Hoboken). 2018 Feb;70(2):197-204. doi: 10.1002/acr.23266.

Supplemental Content

Loading ...
Support Center